NASDAQ:VCYT Veracyte (VCYT) Stock Forecast, Price & News $26.72 +0.53 (+2.02%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$26.12▼$26.9650-Day Range$20.58▼$26.7252-Week Range$14.92▼$32.40Volume526,473 shsAverage Volume612,483 shsMarket Capitalization$1.93 billionP/E RatioN/ADividend YieldN/APrice Target$30.20 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Veracyte MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside13.0% Upside$30.20 Price TargetShort InterestBearish5.15% of Shares Sold ShortDividend StrengthN/ASustainability-1.01Upright™ Environmental ScoreNews Sentiment0.58Based on 7 Articles This WeekInsider TradingSelling Shares$1.56 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.55) to ($0.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 starsMedical Sector816th out of 983 stocksMedical Laboratories Industry19th out of 22 stocks 2.3 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.20, Veracyte has a forecasted upside of 13.0% from its current price of $26.72.Amount of Analyst CoverageVeracyte has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.15% of the outstanding shares of Veracyte have been sold short.Short Interest Ratio / Days to CoverVeracyte has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Veracyte has recently increased by 0.81%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreVeracyte has received a 68.22% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Diagnostic test kits", "Genomics analysis tools", and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Veracyte is -1.01. Previous Next 2.5 News and Social Media Coverage News SentimentVeracyte has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Veracyte this week, compared to 3 articles on an average week.Search Interest3 people have searched for VCYT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,563,075.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Veracyte is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow in the coming year, from ($0.55) to ($0.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -65.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -65.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Veracyte (NASDAQ:VCYT) StockVeracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.Read More Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address VCYT Stock News HeadlinesJune 3, 2023 | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Receives $31.00 Consensus Price Target from AnalystsMay 30, 2023 | finance.yahoo.comVeracyte, Inc.'s (NASDAQ:VCYT) Revenues Are Not Doing Enough For Some InvestorsJune 4, 2023 | Behind the Markets (Ad)Laser breakthrough could send stock soaring 2,467%Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...May 25, 2023 | benzinga.comNew Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte's Decipher GRID To Help Advance Molecular Understanding of Prostate CancerMay 24, 2023 | finance.yahoo.comNew Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung CancerMay 22, 2023 | finance.yahoo.comHere's Why This Little-Known Growth Stock Is a BuyMay 19, 2023 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Coverage Initiated by Analysts at StockNews.comMay 17, 2023 | msn.comLooking Into Veracyte's Return On Capital EmployedJune 4, 2023 | Legacy Research (Affiliate) (Ad)From -60% Account to Doubling His Money?After helping his readers double their money 13 TIMES in the last year alone… There’s ONE person trader Jeff Clark has NOT been able to help! His 23-year-old son, Grant.May 16, 2023 | seekingalpha.comVeracyte: Investing In The Future Of Genomic DiagnosticsMay 11, 2023 | americanbankingnews.comAnalysts Set Veracyte, Inc. (NASDAQ:VCYT) PT at $31.00May 10, 2023 | theglobeandmail.comA New Groundbreaking Tool to Detect Colon Cancer EarlierMay 10, 2023 | msn.comStephens & Co. Reiterates Veracyte (VCYT) Overweight RecommendationMay 5, 2023 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Q1 2023 Earnings Call TranscriptMay 4, 2023 | seekingalpha.comVeracyte, Inc. 2023 Q1 - Results - Earnings Call PresentationMay 4, 2023 | finance.yahoo.comVeracyte Announces First Quarter 2023 Financial ResultsMay 3, 2023 | finance.yahoo.comVeracyte Announces Release of Inaugural ESG ReportMay 3, 2023 | americanbankingnews.comVeracyte (VCYT) to Release Quarterly Earnings on ThursdayMay 1, 2023 | finance.yahoo.comThree Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International ConferenceMay 1, 2023 | benzinga.comFindings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic ClassifierApril 28, 2023 | venturebeat.comAcuamark Diagnostics Welcomes Giulia Kennedy, Former Chief Scientific and Chief Medical Officer of Veracyte, to its Board of DirectorsApril 28, 2023 | nasdaq.comWall Street Analysts See a 40.19% Upside in Veracyte (VCYT): Can the Stock Really Move This High?April 27, 2023 | finance.yahoo.comVeracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual MeetingApril 21, 2023 | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Director Sells $749,360.00 in StockApril 18, 2023 | finance.yahoo.comThe five-year returns have been strong for Veracyte (NASDAQ:VCYT) shareholders despite underlying losses increasingApril 16, 2023 | thestreet.comVeracyte Dips After CMS Proposes Reimbursement Rate ReductionApril 15, 2023 | money.usnews.comVeracyte IncSee More Headlines VCYT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VCYT Company Calendar Last Earnings5/04/2023Today6/03/2023Next Earnings (Estimated)8/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCYT CUSIPN/A CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees761Year Founded2006Price Target and Rating Average Stock Price Forecast$30.20 High Stock Price Forecast$35.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+13.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,560,000.00 Net Margins-9.70% Pretax Margin-9.66% Return on Equity-2.83% Return on Assets-2.63% Debt Debt-to-Equity RatioN/A Current Ratio4.49 Quick Ratio4.25 Sales & Book Value Annual Sales$296.54 million Price / Sales6.53 Cash FlowN/A Price / Cash FlowN/A Book Value$14.93 per share Price / Book1.79Miscellaneous Outstanding Shares72,420,000Free Float70,317,000Market Cap$1.94 billion OptionableOptionable Beta1.38 Social Links Key ExecutivesMarc A. StapleyChief Executive Officer & DirectorRebecca ChambersChief Financial OfficerRichard T. KloosExecutive Medical DirectorSteven FrenchChief Information Officer & Senior Vice PresidentRobert BraininChief Business Officer & Executive Vice PresidentKey CompetitorsRadNetNASDAQ:RDNTFulgent GeneticsNASDAQ:FLGTViridian TherapeuticsNASDAQ:VRDNProgenityNASDAQ:PROGGuardant HealthNASDAQ:GHView All CompetitorsInsiders & InstitutionsMuna BhanjiSold 1,539 sharesTotal: $39,875.49 ($25.91/share)ProShare Advisors LLCSold 952 shares on 5/26/2023Ownership: 0.020%Legato Capital Management LLCBought 8,297 shares on 5/25/2023Ownership: 0.047%Capital Impact Advisors LLCBought 8,833 shares on 5/23/2023Ownership: 0.017%Putnam Investments LLCSold 36,406 shares on 5/22/2023Ownership: 0.203%View All Insider TransactionsView All Institutional Transactions VCYT Stock - Frequently Asked Questions Should I buy or sell Veracyte stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCYT shares. View VCYT analyst ratings or view top-rated stocks. What is Veracyte's stock price forecast for 2023? 6 Wall Street research analysts have issued 1 year target prices for Veracyte's shares. Their VCYT share price forecasts range from $22.00 to $35.00. On average, they predict the company's stock price to reach $30.20 in the next twelve months. This suggests a possible upside of 13.0% from the stock's current price. View analysts price targets for VCYT or view top-rated stocks among Wall Street analysts. How have VCYT shares performed in 2023? Veracyte's stock was trading at $23.73 at the start of the year. Since then, VCYT stock has increased by 12.6% and is now trading at $26.72. View the best growth stocks for 2023 here. When is Veracyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023. View our VCYT earnings forecast. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings data on Thursday, May, 4th. The biotechnology company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The biotechnology company earned $82.40 million during the quarter, compared to analyst estimates of $75.75 million. Veracyte had a negative trailing twelve-month return on equity of 2.83% and a negative net margin of 9.70%. Veracyte's revenue was up 21.5% compared to the same quarter last year. During the same period last year, the business posted ($0.20) EPS. What ETFs hold Veracyte's stock? ETFs with the largest weight of Veracyte (NASDAQ:VCYT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), ARK Genomic Revolution ETF (ARKG), Invesco Dynamic Biotechnology & Genome ETF (PBE), Global X Telemedicine & Digital Health ETF (EDOC), ARK Innovation ETF (ARKK), ARK Next Generation Internation ETF (ARKW), ROBO Global Artificial Intelligence ETF (THNQ) and ROBO Global Healthcare Technology and Innovation ETF (HTEC). What guidance has Veracyte issued on next quarter's earnings? Veracyte issued an update on its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $330.00 million-$340.00 million, compared to the consensus revenue estimate of $330.51 million. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO). What is Veracyte's stock symbol? Veracyte trades on the NASDAQ under the ticker symbol "VCYT." Who are Veracyte's major shareholders? Veracyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.66%), Wellington Management Group LLP (9.87%), BlackRock Inc. (9.12%), State Street Corp (5.76%), Artisan Partners Limited Partnership (5.01%) and Sumitomo Mitsui Trust Holdings Inc. (4.57%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho, Muna Bhanji and Robert S Epstein. View institutional ownership trends. How do I buy shares of Veracyte? Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Veracyte's stock price today? One share of VCYT stock can currently be purchased for approximately $26.72. How much money does Veracyte make? Veracyte (NASDAQ:VCYT) has a market capitalization of $1.94 billion and generates $296.54 million in revenue each year. The biotechnology company earns $-36,560,000.00 in net income (profit) each year or ($0.41) on an earnings per share basis. How many employees does Veracyte have? The company employs 761 workers across the globe. Does Veracyte have any subsidiaries? The following companies are subsidiares of Veracyte: Allegro Diagnostics, Decipher Biosciences Inc., Decipher Corp., Delight Merger Sub II LLC, HalioDx Inc., Veracyte Global B.V., Veracyte International Corp., and Veracyte SAS.Read More How can I contact Veracyte? Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301. This page (NASDAQ:VCYT) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.